Novonesis led Europe's Stoxx 600 index after reporting better-than-expected organic sales growth. The company, which develops enzymes, probiotics and other biological products, saw its stock jump following the earnings release.

The sales performance exceeded consensus estimates, prompting Novonesis to raise its full-year guidance. This positive revision reflects strong demand for its specialty ingredients across food, health and industrial applications.

Shares of Novonesis surged in morning trading, making it the top performer on the Stoxx 600. The Danish company has benefited from growing consumer preference for natural and sustainable ingredients in recent quarters.

Analysts noted that the earnings beat and guidance raise underscore Novonesis' resilient business model and pricing power. The company's focus on innovation and sustainability continues to drive growth despite challenging macroeconomic conditions.

Wall Street Journal Markets reported that Novonesis expects continued momentum through the remainder of the year, supported by new product launches and expansion in emerging markets.